Knee-Deep in Data: Why "More Cells" Changes Everything in Regenerative Medicine

If you’ve spent any time reading about regenerative medicine for joint pain, you’ve probably noticed two completely different storylines floating around.

Storyline A says stem cells are a miracle cure for bad knees. Storyline B says they’re overhyped science fiction that doesn't deliver long-term results.

So, which is it?

A landmark paper published in Cellular & Molecular Immunology by researchers Griffin Copp, Kevin P. Robb, and Sowmya Viswanathan looked at the real data to find out. Instead of asking the generic question "Do stem cells work?", they asked a much more precise one: Which cells, for which patients, and at what dose?

The researchers analyzed 26 clinical studies (15 randomized controlled trials and 11 non-randomized studies) covering 610 patients. The verdict? Stem cells do work as a therapeutic class for knee osteoarthritis — but only if you give the joint enough of them.

The Big Finding: More Than Just Pain Relief

When looking at trials using culture-expanded mesenchymal stem cells (MSCs), the results were overwhelmingly positive:

• 12 out of 15 randomized controlled trials showed significant improvements in pain and symptoms compared to where patients started.
• 11 out of 15 trials proved superior to control groups at the study’s end.
• 18 out of 21 clinical studies evaluating structural changes saw actual evidence of cartilage protection or repair via MRI or joint imaging.

That last point is huge. Most conventional knee treatments (like cortisone shots or painkillers) just mask symptoms while the joint continues to wear down. Culture-expanded MSCs showed real promise in protecting the joint structure itself.

Why Dose Is the Missing Puzzle Piece

Why have some previous stem cell trials failed or yielded mixed results? The review points straight to dose.

Think of it like taking an aspirin for a severe migraine. If you only take a micro-fraction of a milligram, the aspirin isn't "broken" or useless, you simply didn't take enough to trigger a biological effect.

Stem cells work the same way. The review highlighted a clear trend: moderate-to-higher doses (specifically between 20 million and 100 million cells) correlated with significantly better pain relief and structural cartilage outcomes.

For instance, one study cited in the review compared doses of 10 million, 50 million, and 100 million cells. The results? Only the 100-million-cell group showed significant increases in cartilage volume and reductions in cartilage defects. The lower doses simply weren't enough to do the heavy lifting.

Same-Day vs. Culture-Expanded: The Gold Standard

This dose trend reveals a critical truth about how stem cell procedures are performed.

Many clinics offer same-day procedures, where tissue (like fat or bone marrow) is harvested and reinjected hours later. While this isn't "bad," same-day processing fundamentally cannot deliver the cell counts required for true structural repair. You simply can't pull 50 to 100 million viable MSCs out of a single same-day extraction without taking an unfeasible amount of tissue.

This is where culture expansion comes in:

• Harvest: A small, comfortable sample of cells is collected.
• Grow: The cells are multiplied under strict lab conditions over several weeks.
• Deliver: The patient receives a precise, highly concentrated therapeutic dose (tens to hundreds of millions of cells).

Culture expansion is the bridge. It’s not about bashing same-day extractions; it’s simply acknowledging that same-day procedures are mathematically insufficient for reaching the cell doses shown to protect and repair cartilage.

What This Means for the Future of Knee Care

The research by Copp, Robb, and Viswanathan establishes culture expansion as the quality benchmark for cell therapy.

Regenerative medicine is moving away from "one-size-fits-all" promises. The future isn't just about getting "stem cells". It's about getting the right cells, in the right numbers, tailored to your specific joint environment.

This is precisely why Forever Labs is expanding access to culture-expanded cell therapy through our network of board-certified physicians. As the research makes clear, the difference between a same-day procedure and a properly dosed treatment isn't a matter of preference; it's a matter of biological threshold. 

By partnering with physicians equipped to deliver cells at the concentrations shown to drive real structural outcomes, we're aligning our network with what the evidence actually supports, not just what's fastest or most convenient. For patients exploring regenerative options for joint health, that distinction matters — and it's one we intend to lead on.

Source Study: Copp, G., Robb, K.P., & Viswanathan, S. (2023). "Culture-expanded mesenchymal stromal cell therapy: does it work in knee osteoarthritis? A pathway to clinical success." Cellular & Molecular Immunology, 20(6), 626–650.